Evotec Launches PanOmics PanHunter Data Analytics Platform at Bio-IT World

News and research before you hear about it on CNBC and others. Claim your one week free trial for StreetInsider Premium here.


HAMBURG, GERMANY/ACCESSWIRE/October 18, 2022/ Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/TecDAX)(ISIN:DE0005664809)(NASDAQ:EVO) today announced the launch of the first commercial version of its PanOmics PanHunter data analytics platform at Bio-IT World (October 18-19 in Berlin, Germany). PanHunter is Evotec’s PanOmics data access and analytics platform and has been successfully developed and used internally and in industry-shaping drug discovery partnerships for many years. Evotec now makes PanHunter available to its collaborators and partners as a software product as a service (“SaaS”).

PanHunter was born out of Evotec’s commitment to patient-driven drug discovery driven by PanOmics. The amount of PanOmics data available is growing at an exponential rate in the public domain and in the pharmaceutical industry. More PanOmics data has been generated in the past two years than in all previous years combined. This PanOmics data contains an overwhelming amount of information about the condition of the respective patients, the molecular biology background and the causes of the diseases. To extract this information and new knowledge from data, it is essential to use the most intelligent and easy to use analytical tools and to make them available to all scientists of all disciplines.

PanHunter is unique in its ability to integrate PanOmics data analysis, designed as an easy-to-use yet fully comprehensive PanOmics data analysis platform. It thus supports, for example, the stratification of patient populations via molecular mechanisms and the prediction of efficacy and toxicity profiles of drug candidates based on appropriate data inputs. With the launch of the first commercial version of the software at Bio-IT World Europe, Evotec is making PanHunter available to interested partners to accelerate their data-driven research.

Dr. Cord Dohrmann, Scientific Director of Evotec, commented: “In the ever-accelerating world of omics-based drug discovery, we are thrilled to release PanHunter. PanHunter is our contribution to enabling scientists to manage huge, high-dimensional datasets to better understand diseases at the global level. molecular level. A better molecular understanding of disease as well as drug candidates accelerate the drug discovery process and improve the likelihood of pre-clinical and clinical success.”

Dr. Matthias Evers, Chief Commercial Officer of Evotec, said: “With our first commercial release, we are boldly asserting that the future of successful drug discovery lies in the convergence of science and technology. With PanHunter, we are enabling scientists from all disciplines to explore this potential and engaging in patient-driven, PanOmics-informed drug discovery towards deep understanding of disease and obtaining actionable insights is another step in overcoming the limitations of a reductionist R&D approach and use AI to unlock disease understanding and improve success rates (“POS”).”

For more information, please follow this link on the PanHunter website or contact us via [email protected] . To continue reading, follow this link to our latest DDup edition on PanHunter, including user interviews and case studies.

Evotec is a life sciences company with a unique business model that pursues its mission to discover and develop highly effective treatments and bring them to patients. The Company’s multi-modality platform includes a unique combination of innovative technology, data and science for the discovery, development and production of first-class, first-class pharmaceuticals. Evotec leverages this “data-driven R&D highway to cure” for proprietary projects and within a network of partners including all Top 20 Pharma and over 800 biotech companies, academic institutions, as well as other health actors. Evotec has strategic activities in a wide range of currently underserved therapeutic areas, including neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world’s first pipeline of innovative co-owned therapeutics and has to date established a portfolio of over 200 proprietary and co-owned R&D projects, from early discovery to clinical development. Evotec operates worldwide with over 4,500 highly qualified people. The Company’s 16 sites offer highly synergistic technologies and services and function as complementary centers of excellence. For more information, visit www.evotec.com and follow us on Twitter @Evotec and LinkedIn .

This announcement contains forward-looking statements regarding future events, including the proposed offering and listing of Evotec’s securities. Words such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “intend”, “may”, “could”, “plan”, “potential”, “should”, “target”, ” ” and variations of these words and similar expressions are intended to identify forward-looking statements. These statements include comments regarding Evotec’s expectations for revenue, group EBITDA and non-partnership R&D expenditure. These forward-looking statements are based on currently available information and on expectations and assumptions that Evotec believed were reasonable at the time such statements were made. No assurance can be given that these expectations will prove to be correct. These statements involve known and unknown risks and are based on a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond Evotec’s control. Evotec expressly disclaims any obligation or undertaking to publicly release any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec’s expectations with respect thereto or any change in events, conditions or circumstances about which any statement is based.

Evotec SE media contact:
Gabriele Hansen, SVP Head of Global Corporate Communications, Phone: +49.(0)40.56081-255, [email protected]

Hinnerk Rohwedder, Senior Corporate Communications Specialist, tel. : +49.(0)151 4070-4843, [email protected]

Evotec SE IR contact:
Volker Braun, SVP Head of Global Investor Relations & ESG, Phone: +49.(0)40.56081-775, [email protected]


See the source version on accesswire.com:

Comments are closed.